STOCK TITAN
  1. Home
  2. Sec-filings
  3. VERA
  4. [8-K] Vera Therapeutics, Inc. Reports Material Event

FDA grants accelerated approval to Vera Therapeutics (NASDAQ: VERA) drug TRUTAKNA

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Vera Therapeutics reported that the U.S. Food and Drug Administration has granted accelerated approval for its drug TRUTAKNA™ (atacicept-vymj) as of July 7, 2026. The therapy is approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy who are at risk for disease progression.

This represents Vera’s transition into a commercial-stage company for IgA nephropathy, with an FDA-cleared product aimed at a serious kidney disease where reducing protein in the urine can help slow long-term damage.

Positive

  • FDA accelerated approval for TRUTAKNA on July 7, 2026 gives Vera Therapeutics an approved therapy for adults with primary immunoglobulin A nephropathy at risk for disease progression, marking a significant regulatory and commercial milestone.

Negative

  • None.

Insights

FDA accelerated approval of TRUTAKNA is a major milestone for Vera.

Vera Therapeutics received U.S. FDA accelerated approval for TRUTAKNA to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for progression. Accelerated approval is typically based on a surrogate endpoint reasonably likely to predict clinical benefit.

This moves Vera into the ranks of companies with an approved product in a serious kidney disease. While the excerpt does not detail post-approval study requirements, accelerated approvals usually require confirmatory trials, so long‑term commercial value will depend on sustaining safety and efficacy evidence.

Investors will look to subsequent company communications and future filings for details on launch timing, pricing, payer coverage, and any confirmatory study plans tied to the accelerated approval granted on July 7, 2026.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
FDA accelerated approval date July 7, 2026 TRUTAKNA approval for IgA nephropathy
Par value per share $0.001 per share Class A common stock par value
Commission file number 001-40407 SEC registration reference for Vera Therapeutics
Headquarters ZIP code 94005 Brisbane, California principal executive offices
accelerated approval regulatory
"the U.S. Food and Drug Administration has granted TRUTAKNA™ (atacicept-vymj) accelerated approval"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.
proteinuria medical
"accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy"
Proteinuria is when abnormal amounts of protein are found in a person's urine. It can be a sign that the kidneys aren't working properly, since healthy kidneys usually prevent most proteins from passing into urine. Detecting proteinuria helps doctors identify and monitor kidney problems early.
primary immunoglobulin A nephropathy medical
"adults with primary immunoglobulin A nephropathy at risk for disease progression"
Emerging growth company regulatory
"Emerging growth company Item 8.01 Other Events."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Class A common stock financial
"Class A common stock, $0.001 par value per share"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What did Vera Therapeutics (VERA) announce regarding TRUTAKNA?
Vera Therapeutics announced that the U.S. FDA granted accelerated approval for TRUTAKNA (atacicept-vymj). The drug is cleared to reduce proteinuria in adults with primary immunoglobulin A nephropathy who are at risk for disease progression, marking Vera’s first approved product.

What condition is TRUTAKNA now approved to treat for Vera Therapeutics (VERA)?
TRUTAKNA is approved to treat adults with primary immunoglobulin A nephropathy at risk for disease progression. The approval specifically covers reducing proteinuria, which is excess protein in the urine and an important marker of ongoing kidney damage in this chronic disease.

What type of FDA approval did Vera Therapeutics (VERA) receive for TRUTAKNA?
Vera Therapeutics received an FDA accelerated approval for TRUTAKNA. Accelerated approval allows earlier access to treatments for serious conditions using a surrogate endpoint, in this case reduction of proteinuria in primary immunoglobulin A nephropathy, subject to the usual ongoing evidence expectations.

When did the FDA grant accelerated approval to Vera Therapeutics’ TRUTAKNA?
The FDA granted accelerated approval to TRUTAKNA on July 7, 2026. This date marks Vera Therapeutics’ transition toward commercializing a therapy aimed at reducing proteinuria in adults with primary immunoglobulin A nephropathy who face risk of worsening kidney disease.

How does TRUTAKNA’s approval affect Vera Therapeutics’ business outlook?
TRUTAKNA’s accelerated approval gives Vera Therapeutics an FDA-cleared product in IgA nephropathy. Having an approved therapy for adults at risk of disease progression can significantly enhance the company’s commercial potential, pending details on launch, market uptake, and any confirmatory evidence requirements.
false000183182800018318282026-07-072026-07-07

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 07, 2026

 

 

Vera Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40407

81-2744449

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2000 Sierra Point Parkway, Suite 1200

 

Brisbane, California

 

94005

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 770-0077

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Class A common stock, $0.001 par value per share

 

VERA

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 8.01 Other Events.

On July 7, 2026, Vera Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted TRUTAKNA™ (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Vera Therapeutics, Inc.

 

 

 

 

Date:

July 7, 2026

By:

/s/ Marshall Fordyce

 

 

 

Marshall Fordyce, M.D.
Chief Executive Officer

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Other Documents